MPH Health Care AG
XETRA:93M1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (46.5), the stock would be worth €22.27 (6% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 44.1 | €21.1 |
0%
|
| 3-Year Average | 46.5 | €22.27 |
+6%
|
| 5-Year Average | 5.1 | €2.43 |
-88%
|
| Industry Average | 16.9 | €8.1 |
-62%
|
| Country Average | 17.7 | €8.47 |
-60%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
MPH Health Care AG
XETRA:93M1
|
90.3m EUR | 44.1 | -0.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 35.4 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 29.2 |
| Max | 2 317.8 |
Other Multiples
MPH Health Care AG
Glance View
MPH Health Care AG is an investment company, which engages in the acquisition and development of companies and shares in companies from the healthcare industry. The company is headquartered in Berlin, Berlin. The company went IPO on 2009-01-01. The firm focuses on the purchase, development and sale of companies and shares in companies from the healthcare market. The firm's portfolio comprises HAEMATO AG, M1 Kliniken AG and MPH Ventures. HAEMATO AG is a pharmaceutical company that offers generics for the therapies of cancer, human immunodeficiency virus (HIV) and other chronic diseases. M1 Kliniken AG focuses on the medicinal beauty market and develops and sells pharmaceutical and medical products and services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. MPH Ventures operates as venture capitalist and invests in Pharmigon GmbH, a company specialized in cytostatic admixture and concomitant medications, as well as in the real estate company CR Capital Real Estate AG.
